Products
Ciduvectamig Biosimilar Bispecific Antibody (TMEFF2 × CD3) for Research
Cat No.: GMP-Bios-INN-1130
Anti-TMEFF2 therapeutic antibody (Pre-made Ciduvectamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ciduvectamig (development code JNJ-70218902) is a bispecific antibody targeting TMEFF2 and CD3. It is developed by Janssen Research & Development for solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1130-1mg | 1mg | |
| GMP-Bios-INN-1130-10mg | 10mg | |
| GMP-Bios-INN-1130-100mg | 100mg | |
| GMP-Bios-INN-1130-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ciduvectamig biosimilar, Bispecific mAb, Anti-TMEFF2;CD3E Antibody: Anti-TMEFF2/Tomoregulin-2/TR-2/Hyperplastic polyposis protein 1 therapeutic antibody |
| INN Name | Ciduvectamig |
| Target | TMEFF2;CD3E |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4;G4 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Janssen Research & Development |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Prostate cancer |
| Production | na |
| Development Tech | na |
